2014 Chabner Colloquium Focuses on Collaboration in Cancer Trials

Share Article

Registration is now open for the Society for Translational Oncology (STO) 2014 Chabner Colloquium: Collaboration in Cancer Trials.

News Image

Registration is now open for the Society for Translational Oncology (STO) 2014 Chabner Colloquium: Collaboration in Cancer Trials. The continuing medical education (CME) symposium is jointly provided by The Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO's official journal. The meeting will be held November 10-11, 2014 at The Liberty Hotel in Boston, Massachusetts.

The symposium will provide updates on the most promising targets for development of new cancer treatments. Physician-scientists, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to view the agenda, confirmed faculty, and register online at http://bit.ly/chabner2014.

Offered for the fourth year, the 2014 Chabner Colloquium includes presentations on emerging molecular targets for cancer treatments—with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. and international research centers will address work in progress in a broad variety of topics in cancer therapeutics. Invited speakers hail from renowned institutions such as The Massachusetts General Hospital Cancer Center, The Broad Institute at the Massachusetts Institute of Technology, the Dana Farber Cancer Institute, the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and The Royal Marsden.

The meeting is named for Dr. Bruce A. Chabner, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states “It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."
On Monday, November 10th, the session topics include lectures on the new insights into the metabolic regulation of cancer growth, immunotherapy and hematological malignancies.

The day concludes with a forum of junior faculty members from Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute sharing their recent work.

Tuesday, November 11th, the session topics include lectures on metabolic lesions in cancer and genetic profiling for treatable mutations.

To register and get 50% off the rate, go to http://bit.ly/chabner2014 and use promotional code CHABNER50 for Physicians Clinicians/Researchers and FELLOW50 for Physician Residents/Fellows.

STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This two day symposium will be designated for a maximum of 10 AMA PRA Category 1 Credit(s)™.

For more information contact STO at (919) 433-0489 or CMEadmin(at)sto-online(dot)org.

# # #

About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://www.sto-online.org.

About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its nineteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.

About The Massachusetts General Hospital Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.

Known for providing customized, innovative treatments and compassionate care to both adults and children, the Massachusetts General Hospital Cancer Center comprises 25 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services.

The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.

For more information, contact:
Jen Homan, Program Manager, STO
(919) 433-0489

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website